Document Classification

Section Type: METHODS

Text: Between May 1995 and July 1998, a total of 70 patients with high-intermediate risk or high risk aggressive NHL, according to the International Prognostic Index, were enrolled and randomly assigned to receive either eight cycles of standard CHOP (cyclophosphamide 750 mg/m (2), doxorubicin 50 mg/m (2), vincristine 1. 4 mg/m (2) and prednisolone 100 mg for 5 days) every 2 weeks, or six cycles of dose-escalated CHOP (cyclophosphamide 1500 mg/m (2), doxorubicin 70 mg/m (2), vincristine 1. 4 mg/m (2) and prednisolone 100 mg for 5 days) every 3 weeks.